GM-CSF stimulates an anti-tumor immune response through priming CD4+ and CD8+ T cells, in part through recruiting and activating dendritic cells, and is currently being investigated for use in pancreatic cancer vaccines (4, 5, 58–60). This evidence concerns the gene CD8A and familial pancreatic carcinoma.